Multiple Myeloma Market Snapshot: New Drugs And Big Changes
Executive Summary
The multiple myeloma treatment landscape is poised for a shakeup following the FDA approval of three new drugs to treat the incurable cancer, but with all the competition, determining which drugs to use when and in which patients won’t necessarily be straightforward.
You may also be interested in...
Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit
Despite several new entrants to the multiple myeloma market, Datamonitor Healthcare forecasts that drug sales between 2017 and 2026 will peak in 2022 when Revlimid generics hit the market. J&J's Darzalex will become the new best-seller, but generate a fraction of Revlimid's sales.
Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit
Despite several new entrants to the multiple myeloma market, Datamonitor Healthcare forecasts that drug sales between 2017 and 2026 will peak in 2022 when Revlimid generics hit the market. J&J's Darzalex will become the new best-seller, but generate a fraction of Revlimid's sales.
Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control
With an array of high quality drugs and preference for stacked combo therapy in multiple myeloma, the disease is poised to become a testing ground for cost containment in oncology.